Before dry granulation or direct compression, veterinary-grade Qingre Powder is conditioned to a loss-on-drying value not exceeding 5.0% w/w as determined by USP <731>; residual moisture above 6.0% w/w is the boundary at which punch filming and die-wall adhesion on 16-station rotary tablet presses become difficult to control. The milled API is passed through a pin mill fitted with a 0.6 mm screen until the D90 value falls below 150 µm by laser diffraction per USP <429> or ISO 13320:2020; this particle-size window prevents segregation of fibrous botanical particles while retaining compressibility. A representative direct-compression formulation consists of 25–35% w/w Qingre Powder, 45–55% w/w microcrystalline cellulose PH102, 10–15% w/w lactose monohydrate, 3–5% w/w croscarmellose sodium, 0.5–1.0% w/w colloidal silicon dioxide, and 0.5% w/w magnesium stearate. The lubricant is added last after a 5-minute preblend with the glidant and disintegrant. On an 8 mm round concave tooling set, compression force is maintained in the 8–14 kN range; tablet breaking force between 70 N and 100 N, measured per USP <1217>, is the release threshold for a 0.5 g tablet. Friability is held at or below 1.0% after 100 revolutions in a USP <1216> friabilator. Disintegration in 900 mL purified water at 37±2°C is complete within 30 minutes when tested under the Ph. Eur. 2.9.1 procedure. Published data for this specific botanical API configuration remains limited; however, capping and lamination are recurrent at compression forces above 14 kN because of elastic recovery from high-fiber botanical material. The terminal dosage forms are 0.5 g and 1.0 g veterinary tablets intended for oral administration to swine and poultry.

What Limits Marker Homogeneity in Low-Inclusion Medicated Premixes?

Low-inclusion premixes prepared at 0.5% w/w or 2.0% w/w of veterinary-grade Qingre Powder must not be charged as an undiluted minor component into a ribbon mixer. Instead, geometric preblending is performed with a ground corncob or rice hull carrier having a particle-size D50 of 300–600 µm; each dilution step should not exceed a 4:1 carrier-to-active ratio, and the preblend is passed through a 500 µm sieve before the main blend. Under EU 2019/6 Annex II, medicated feed intermediates require validation of homogeneous distribution; for a 0.5% premix, the coefficient of variation of a marker alkaloid across 10 sampling points should remain at or below 5.0%. Ribbon mixers with a working volume of 60% and a tip speed around 0.8–1.2 m/s achieve acceptable uniformity in 12–18 minutes; however, published data for this specific API–carrier system is limited, and each batch should be verified by near-infrared spectroscopy in the 950–1650 nm region calibrated for berberine-type or baicalin markers. Copper sulfate, zinc oxide, ferrous carbonate, and acidified choline chloride premixes should be segregated because transition-metal ions accelerate oxidation of phenolic hydroxyl groups; if final feed is pelleted, steam conditioning above 75°C for more than 30 seconds should be evaluated for marker loss on a pilot scale because published data for this specific botanical premix is limited. The terminal product is a 2.0% w/w or 0.5% w/w veterinary premix for incorporation into complete feed at 2–5 kg per tonne for swine, broiler, and layer rations.

Sterile Injectable Processing: Endotoxin, Turbidity, and pH Titration Limits for Botanical Extracts

Crude Qingre Powder is not suitable for direct injection. The injectable route requires a purified aqueous or hydroalcoholic extract, typically prepared by decoction or percolation, followed by clarification through 0.45 µm and 0.22 µm polyethersulfone membranes. The liquid is standardized to total alkaloid content, with berberine hydrochloride or paeonol as marker compounds; final pH is titrated to 6.0–7.0 with citrate or phosphate buffer because tannin–protein aggregation increases at pH values above 7.5 and acidification below 4.0 causes precipitation of weakly acidic flavonoids. Bacterial endotoxin limits are derived from the maximum intended dose under USP <85>; a preliminary process-development limit of ≤0.50 EU/mL is applied for a 5 mL per 10 kg body weight intramuscular injection, but the final limit must be calculated from the species-specific endotoxin threshold in the registration dossier. The filtered solution is filled into Type I borosilicate glass vials or non-PVC polyolefin bags because polyvalent cations leached from inferior container glass can form phytic acid chelates. Terminal sterilization at 121°C for 15 minutes reduces marker peak area in some botanical extracts; aseptic filtration is therefore preferred unless forced-degradation studies confirm that the alkaloid fraction remains within 90.0–110.0% of label after one sterilization cycle. Insoluble particulate testing under USP <788> by light obscuration is mandatory; for small-volume parenterals, not more than 6000 particles ≥10 µm and not more than 600 particles ≥25 µm per container are typical Pharmacopeial thresholds. High-pressure homogenization at 500–800 bar may be required if a fine suspension rather than a solution is developed, but particle size after processing must remain below 5 µm for intramuscular use to avoid injection-site irritation. Published data for this specific Qingre extract configuration is limited; therefore, pH-solubility and terminal sterilization studies must be repeated for each batch of botanical input. The terminal product is a sterile injectable solution or suspension for intramuscular or subcutaneous administration to cattle, swine, or companion species.

For oral drench and drinking-water solutions, veterinary-grade Qingre Powder is dispersed at 0.5–1.0 g/L into potable water that has been softened or treated to keep total hardness below 250 ppm as CaCO3; higher hardness reduces dissolution of flavonoid glycosides and increases sedimentation within 30 minutes. The dispersion is passed through an 80-mesh inline screen before reaching proportioning pumps or header tanks. A reconstituted water medication should be used within 24 hours when stored below 30°C; beyond that window, aerobic microbial counts can rise above 10³ CFU/mL in unpreserved systems, and in-line UV or chlorination is not a substitute for terminal sterility. For multi-day delivery in automatic watering systems, citric acid is added to pH 4.0–5.5 and potassium sorbate at 0.1% w/w is used as a preservative; this pH band minimizes oxidation of berberine-type alkaloids and limits the growth of pathogenic Enterobacteriaceae. Chlorinated alkaline water is incompatible because hypochlorite oxidizes quaternary ammonium alkaloids and aromatic hydroxyl groups, producing unknown degradants. Nipple drinker systems with stagnant dead legs should be flushed every 12 hours to prevent settling of fine botanical residues. Published data for the specific acid–preservative combination is limited; in-use stability should be confirmed by a five-timepoint HPLC assay at 0, 6, 12, 24, and 48 hours. The terminal products are oral drench liquids, bulk oral powders, and drinking-water additives for poultry, pigs, and pre-ruminant calves.

When Qingre Powder Is Filled Into Hard Gelatin or HPMC Capsules Without Prior Granulation

Direct encapsulation of Qingre Powder is governed by flow and moisture rather than by active content. The powder blend should exhibit an angle of repose not greater than 40°, a Carr compressibility index below 25%, and a bulk density above 0.45 g/mL before filling on a high-speed automatic capsule machine. Blending with 0.5% w/w magnesium stearate and 1.0% w/w colloidal silicon dioxide is used to reduce wall friction; however, magnesium stearate concentrations above 1.5% w/w create a hydrophobic film around botanical particles and delay marker dissolution. Capsule fill weight uniformity is monitored by mass variation according to USP <905> Uniformity of Dosage Units; for a 0.5 g fill weight, a relative standard deviation below 4% is maintained across 10 capsules. Hard gelatin shells become brittle below 30% relative humidity and tacky above 60% relative humidity; consequently, HDPE bottles with desiccant capsules are used for stability storage. If aldehyde-mediated crosslinking of gelatin is observed at 40°C and 75% RH under VICH GL3 accelerated stability conditions, replacement with hydroxypropyl methylcellulose capsules is recommended because HPMC shells do not undergo the same crosslinking reaction. The filled capsules are subjected to disintegration testing in 0.1 M HCl at 37±2°C; complete shell rupture and powder dispersion should occur within 20 minutes. Published data for this specific botanical extract in HPMC capsules is limited; therefore, a comparative dissolution profile in water, 0.1 M HCl, and pH 6.8 phosphate buffer is a prerequisite for batch release. The terminal products are 0.25 g and 0.5 g veterinary capsules for oral administration to companion animals or for equine use under prescription.

Wet Granulation Parameters for Effervescent-Free Qingre Granules

Top-spray fluid-bed granulation is applied when a dust-free granule is required for oral administration in feed or by drench. A binder solution of polyvinylpyrrolidone K30 at 3–5% w/w in purified water is sprayed at 10–20 mL/min onto a fluidized powder bed containing Qingre Powder, lactose monohydrate, and microcrystalline cellulose; inlet air temperature is controlled at 50–60°C to maintain product temperature at 30–40°C. The granulation endpoint is defined by loss on drying of 3.0–5.0% w/w determined by USP <731>; overdrying below 2.0% w/w increases granule friability and generates fines below 75 µm, while residual moisture above 6.0% w/w produces blocking in the product hopper. Granules are passed through a 0.8 mm screen and collected with a D50 of 300–800 µm; this range provides rapid dispersion in 500 mL water under gentle stirring within 2–3 minutes. Because the formulation is effervescent-free, no organic acids or carbonate sources are included; effervescent coupling is avoided due to pH-sensitive alkaloid stability. Sachet filling is performed on a vertical form-fill-seal line with desiccant sachets in aluminum-laminated pouches; the terminal product is a 1.0 g or 2.0 g oral granule sachet for reconstitution as a suspension or direct oral administration to swine and poultry. Published data for this specific Qingre granulation is limited; batch release should include sieve analysis, moisture, and HPLC marker assay across three production lots to establish within-lot variability.